Evidence map›Paper›PMID 37559457›Full record

ArticleActa biochimica et biophysica Sinica2023

Synergistic antitumor effects of circularly permuted TRAIL with doxorubicin in triple-negative breast cancer.

Jia Liu, Tienian Zhu, Jiankun Liu, Yujie Cui, Shifang Yang, Ruijing Zhao

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biochimica et biophysica Sinica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Jia LiuDepartment of Oncology, Hebei Medical University, Shijiazhuang 050017, China.
Tienian ZhuDepartment of Oncology, Hebei Medical University, Shijiazhuang 050017, China.
Jiankun LiuDepartment of Oncology, Hebei Medical University, Shijiazhuang 050017, China.
Yujie CuiDepartment of Oncology, Hebei General Hospital, Shijiazhuang 050057, China.
Shifang YangBeijing Sunbio Biotech Co., Ltd., Beijing 100000, China.
Ruijing ZhaoDepartment of Immunology, Hebei Medical University, Key Laboratory of Immune Mechanism and Intervention on Serious Disease in Hebei Province, Shijiazhuang 050017, China.
Affiliated Hospital of Hebei University · CNBethune International Peace Hospital · CNHebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circularly permuted TRAIL (CPT), a novel recombinant TRAIL mutant, is a potent antitumor agent. However, its efficacy in triple-negative breast cancer (TNBC) remains unclear. Treatment with CPT alone and in combination with doxorubicin (Dox) is explored for its effects on the proliferation and apoptosis of MDA-MB-231 (MB231) and MDA-MB-436 (MB436) breast cancer cells

Indexed as

Antineoplastic AgentsBreast NeoplasmsTriple Negative Breast NeoplasmsAnimalsApoptosisCell Line, TumorDoxorubicinFemaleHumansMiceMice, NudeAntineoplastic AgentsDoxorubicinapoptosisdeath receptordoxorubicinTRAILtriple-negative breast cancer

Identifiers

PMID37559457
PMCPMC10449636
OpenAlexW4385693527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.